JAMA Network Home
Sign In
Editor's Pick Research Letter

Cancer Medicine Approvals in the US

JAMA 10.1001/jama.2026.12089

July 30, 2026 at 11:00 AM EDT

Read the full article

This cross-sectional study examines trends in cancer medicine approvals by the US Food and Drug Administration (FDA) for adult solid tumors between 2006 and 2025, including both original and supplemental indication approvals.

Corresponding Author: Bishal Gyawali, MD, PhD, Division of Cancer Care and Epidemiology, Sinclair Cancer Research Institute, Queen’s University, 10 Stuart St, Level 2, Kingston, ON K7L 3N6, Canada (gyawali.bishal@queensu.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.12089?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=073026

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks